DMKPQ — DMK Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$6.66m
- $4.76m
Brief: Adamis Pharmaceuticals Provides Update On Clinical Study Assessing Tempol For The Treatment Of Covid-19
Brief: Adamis Pharmaceuticals Announces Leadership Transition To Support New Phase Of Innovation And Growth
Adamis Pharmaceuticals Corp reports results for the quarter ended in March - Earnings Summary
Adamis Pharmaceuticals Corp expected to post a loss of 3 cents a share - Earnings Preview
Brief: Adamis Pharmaceuticals Reports Full Year 2021 Financial Results And Provides Corporate Update
Adamis Pharmaceuticals Corp expected to post a loss of 4 cents a share - Earnings Preview
Brief: Adamis Pharmaceuticals Announces Results Of Tempol In Omicron Virus Challenge In Hamster Model
Brief: Adamis Pharmaceuticals Issues Nationwide Voluntary Recall Of SYMJEPI Injection
Brief: Adamis Pharmaceuticals Provides Update On Clinical Study Assessing Tempol For The Treatment Of COVID-19
Brief: Adamis Pharmaceuticals Announces Retirement Of Richard C. Williams, Chairman Of The Board
Brief: Adamis Pharmaceuticals’ Clinical Study Assessing Tempol For The Treatment Of COVID-19 Surpasses Enrollment Expectations
Brief: Adamis Pharmaceuticals Provides Enrollment Update Of Subjects In Phase 2/3 Study Of Tempol For The Treatment Of COVID-19
Brief: Adamis Pharmaceuticals Submits Fast Track Application To FDA For Tempol
Brief: Adamis Pharma Updates Comparative Pharmacology Model Data
Brief: Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results And Provides Corporate Update
Adamis Pharmaceuticals Corp expected to post a loss of 6 cents a share - Earnings Preview
Adamis Pharmaceuticals Corp expected to post a loss of 6 cents a share - Earnings Preview
Adamis Pharmaceuticals Corp expected to post a loss of 6 cents a share - Earnings Preview
Adamis Pharmaceuticals Corp expected to post a loss of 6 cents a share - Earnings Preview